In a prostate cancer model, treatment with an oncolytic adenovirus armed with a helper-dependent adenovirus expressing a PD-L1 mini-antibody combined with HER2-CAR-T cells resulted in an enhanced anti-tumor effect both in vitro and in vivo. The gene discussed is ERBB2; the disease is neoplasm.